Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes

Journal of Infectious Diseases

Volumn 174, Issue 2, 1996, Pages 361-366

  Heppner, D G ^a   Gordon, D M ^b   Gross, M ^b   Wellde, B ^b   Leitner, W ^b   Krzych, U ^b   Schneider, I ^b   Wirtz, R A ^b   Richards, R L ^b   Trofa, A ^b   Hall, T ^b   Sadoff, J C ^b   Boerger, P ^b   Alving, C R ^b   Sylvester, D R ^b   Porter, T G ^b   Ballou, W R ^b  

^a Armed Forces Research Institute of Medical Sciences San Francisco   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIBIOTIC AGENT; IMMUNOLOGICAL ADJUVANT; LIPOSOME; MALARIA VACCINE; MEFLOQUINE; PHOSPHORYL LIPID A; RECOMBINANT VACCINE; RLF VACCINE; SPOROZOITE VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEACYLATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENCAPSULATION; ERYTHEMA; FEMALE; FEVER; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALARIA FALCIPARUM; MALE; MYALGIA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SPOROZOITE; VACCINATION; VACCINE PRODUCTION;

EID: 19144370919     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.2.361     Document Type: Article

References (17)

1. Clyde D, McCarthy VC, Miller RM, Woodward WE. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 1975;24:397-401.
2. Herrington D, Davis J, Nardin E, et al. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg 1991;45:539-47.
3. Egan JE, Huffman SL, Haynes JD, et al. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 1993;49:166-73.
4. Zavala F, Cochrane AH, Nardin EH, Nussenweig RS, Nussenzweig V. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J Exp Med 1983;157:1947-53.
5. Ballou WR, Hoffman SL, Sherwood JA, et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1987;1:1277-81.
6. Herrington DA, Clyde DF, Losonsky G, et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987;328:257-9.
7. Gordon DM. Use of novel adjuvants and delivery systems to improve the humoral and cellular immune responses to malaria vaccine candidate antigens. Vaccine 1993;11:591-3.
8. White K, Krzych U, Gordon DM, et al. Induction of cytolytic and antibody responses using Plasmodium falciparum repeatless circumsporozoite protein encapsulated in liposomes. Vaccine 1993;11:1341-6.
9. Malik A, Egan JE, Houghten RA, Sadoff JC, Hoffman SL. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci USA 1991;88:3300-4.
10. Reddy R, Zhou F, Nair S, Huang L, Rouse BT. In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J Immunol 1992;148:1585-9.
11. Zhou F, Huang L. Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes. Vaccine 1993;11:1139-44.
12. Fries LF, Gordon DM, Richards RL, et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci USA 1992;89:358-62.
13. Dame JB, Williams JL, McCutchan TF, et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 1985;225:593-7.
14. Ribi E. Beneficial modification of the endotoxin molecule. J Biol Resp Modif 1984;3:1-9.
15. Alving CR, Schichijo S, Mattsby-Baltzer I, Richards RL, Wassef NM. Preparation and use of liposomes in immunological studies. In: Gregoriadis G, ed. Liposome technology. 2nd ed. Vol 3. Boca Raton, FL: CRC Press, 1993:317.
16. Wirtz RA, Ballou WR, Schneider I, et al. Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. Exp Parasitol 1987;63:166-72.
17. Houghten RA. General method for the rapid solid-phase synthesis of large number of peptides: specificity of antigen-antibody interactions at the level of individual amino acids. Proc Natl Acad Sci USA 1985;82:5131-5.